CAS: 147-52-4; Nafcillin

该化合物是一种半合成二硝基苯丙胺抗生素,主要用于治疗由生成催化素的黄素球菌引起的感染,其特点是乙酯结构,对抗菌活动至关重要.纳非西林耐受某些乙酯的降解,使其能有效抗天然青霉素通常抗药性的细菌的特定菌株.该化合物一般通过注射方式施用,因为肠胃吸收的不良.纳菲林展示了多种抗抗克菌细菌的活动,特别是抗血压球菌,对抑制抗菌性生物的效果较低.其致癌基因突变的基因突飞猛进,其半衰期相对较短,需要多剂量才能有效治疗.常见副作用包括过敏反应,胃肠扰动和对肝功能的潜在影响.同所有抗生酶一样,建议适当的感官测试,以确保其对目标细菌菌株的效果.

结构式图片

欧盟法规

REACH注册ECHA物质ECHA物质C&L通报REACH预注册

上下游产品

CAS号27605-28-3 6β-(2-phenyl-ac... | CAS号551-16-6 6-氨基青霉烷酸 | CAS号55150-29-3 2-乙氧基-1-萘甲酰氯

合成工艺路线路线简述

    6β-[(2-Ethoxy-Naphthalene-1-Carbonyl)-Phenylacetyl-Amino]-Penicillanic Acid 2-(4-Bromo-Phenyl)-2-Oxo-Ethyl Ester置于sodium Thiophenolate体系中,用 乙酸乙酯,N,N-二甲基甲酰胺 用作溶剂,化学反应生成萘夫西林
    参考文献:Busko-Oszczapowicz,I. Et Al.,Roczniki Chemii,1974,Vol. 48,P. 253-261
    标题:Busko-Oszczapowicz,I. Et Al.,Roczniki Chemii,1974,Vol. 48,P. 253-261

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-2024197774-A1
    优先权日:2021-04-16
    标 题:Synthesis of Antimicrobial PVP-coated Bismuth Nanoparticles
    发明人:LOPEZ-RIBOT JOSE; VAZQUEZ-MUNOZ ROBERTO
    权利人:UNIV TEXAS
    摘要:Described herein is a facile, fast, and economical method for the synthesis of BAL-mediated PVP-BiNPs, using basic laboratory instruments and reagents readily available in most laboratories.

    专利号:US-2005186197-A1
    优先权日:2002-08-29
    标 题:Peptide inhibitors of beta lactamases
    发明人:PALZKILL TIMOTHY; HUANG WANZHI
    摘要:Peptide inhibitors of β-lactamases have been identified by the synthesis of peptide arrays using synthesis SPOT technology. These peptide inhibitors of β-lactamase have activity against a broad spectrum of β-lactamases and are useful in a variety of applications.

    专利号:US-2022233673-A1
    优先权日:2019-06-04
    标 题:METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
    发明人:BILLET ANNE; SCHMIDT FRÉDÉRIC; JOHANNES LUDGER; SERVENT DENIS; MOURIER GILLES; TARTOUR ÉRIC; KAY MICHAEL; FULCHER JAMES M
    权利人:INST CURIE; CENTRE NAT RECH SCIENT; INST NAT SANTE RECH MED; COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES CEA; APHP ASSIST PUBLIQUE HOPITAUX DE PARIS; UNIV PARIS; UNIV OF UTAH RESEARCH FOUDATION; UNIV UTAH RES FOUND
    摘要:A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.

    专利号:US-9125880-B2
    优先权日:2002-12-26
    标 题:Polymer conjugates of interferon-beta with enhanced biological potency
    发明人:SAIFER MARK G P; MARTINEZ ALEXA L; WILLIAMS L DAVID; SHERMAN MERRY R
    权利人:SAIFER MARK G P; MARTINEZ ALEXA L; WILLIAMS L DAVID; SHERMAN MERRY R; MOUNTAIN VIEW PHARMACEUTICALS
    摘要:Methods are provided for the synthesis of polymer conjugates of cytokines and receptor-binding antagonists thereof, especially a non-glycosylated interferon-beta, which conjugates retain unusually high biological potency. Preparation of polymer conjugates according to the methods of the present invention diminishes or avoids steric inhibition of receptor-ligand interactions that commonly results from the attachment of polymers to receptor-binding regions of cytokines, as well as to agonistic and antagonistic analogs thereof. The invention also provides conjugates and compositions produced by such methods. The conjugates of the present invention retain a high level of biological potency compared to those produced by traditional polymer coupling methods that are not targeted to avoid receptor-binding domains of cytokines. In assays in vitro, the biological potency of the conjugates of non-glycosylated interferon-beta of the present invention is substantially higher than that of unconjugated interferon-beta and is similar to that of interferon-beta-1a that is glycosylated. The conjugates of the present invention also exhibit an extended half-life in vivo compared to the corresponding unconjugated cytokine. The present invention also provides kits comprising such conjugates and/or compositions, and methods of use of such conjugates and compositions in a variety of diagnostic, prophylactic and therapeutic applications, including treatment of multiple sclerosis.

    专利号:US-2022395555-A1
    优先权日:2020-06-11
    标题:Derivatives of antibiotics
    发明人:FARBER BORIS; FARBER SOF'YA; MARTYNOV ARTUR VIKTOROVICH
    权利人:FARBER BORIS; FARBER SOFYA; MARTYNOV ARTUR VIKTOROVICH
    摘要:Field of application: The invention relates to chemistry, pharmacy and cosmetology, allows to synthesize of supramolecular structure on base antibiotics derivatives for use in pharmacy, cosmetology and pharmacy. n The essence of the invention: a new derivatives of antibiotics based on supramolecular structures and a method for their preparation, characterized in that the supramolecular structures are obtained by combinatorial synthesis of an antibiotic from one source molecule with two or more groups available in the reaction for covalent modification, at least with two different modifiers simultaneously, this creates a mixture of modified derivatives of the original molecule, with a maximum variety of derivatives with forming new supramolecular structure, and as biologically active substances to create pharmaceutical compositions use such supramolecular structure without separation into individual components, and in the reaction a combinatorial mixture of modified derivatives of the original molecule is formed antibiotic, the maximum number of combinations. n Technical result: modified combinatorial derivatives of antibiotics with antimicrobial and antifungal activity against multiresistant and pan drug resistance strains of microorganisms and fungi. Means have a wide spectrum of action, and the supramolecular and combinatorial structure of their tens and hundreds of derivatives eliminates the resistance of microorganisms.
    山东四环药业股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.sdsihuanpharm.com
    企业联系电话:0531-89702887-👤
    📞山东四环药业股份有限公司 ⚠️参考联系方式
    联系人:李经理
    电话:0531-89702887-
    手机:13256103272
    传真:0531-89702886
    邮箱:sales@sdsihuanpharm.com
    通信地址: 山东四环药业股份有限公司
    邮编: 253100
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:山东四环药业股份有限公司
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Kim KY, Frey RJ, Epplen K, Foruhari F. Interaction between warfarin and nafcillin: case report and review of the literature. Pharmacotherapy. 2007 Oct;27(10):1467-70. Review. Review. Review. Review.

    合成参考文献


    参考文献:10.1186/1472-6831-11-21
    摘要:Smith MH, Harms PW, Newton DW, Lebar B, Edwards SP, Aronoff DM. Mandibular Actinomyces osteomyelitis complicating florid cemento-osseous dysplasia: case report. BMC Oral Health. 2011 Jul 21;11():21.
    参考文献:10.1086/491714
    摘要:Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis. 2006 Jan 01;42 Suppl 1():S51–7. doi: 10.1086/491714.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知